Physiologically Based Pharmacokinetic (PBPK) Modeling in Children
2012/06/06 by J S Barrett, Jeffrey S. Barrett, Ornella Della Casa Alberighi +5 · 26 citations
Medicine · Pharmacology, Toxicology and Pharmaceutics · #Pharmaceutical studies and practices #Antibiotics Pharmacokinetics and Efficacy #Pharmacogenetics and Drug Metabolism
paper · doi:10.1038/clpt.2012.64
Abstract
This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and approaches, which were originally developed for the purpose of toxicologic evaluation. Also discussed is the current degree of confidence in using PBPK to support pediatric drug development and registration and the key factors essential for robust results and broader adoption of pediatric PBPK M&S.
Cited by
- State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development
- A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. [europepmc]
- A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. [europepmc]
- Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. [europepmc]
- Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. [europepmc]
- A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. [europepmc]
- Pharmacokinetic studies in infants using minimal-risk study designs. [europepmc]
- Clinical pharmacology in neonates: small size, huge variability. [europepmc]
- Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. [europepmc]
- Pediatric microdose study of [(14)C]paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. [europepmc]
- Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children. [europepmc]
- Influence of Food on Paediatric Gastrointestinal Drug Absorption Following Oral Administration: A Review. [europepmc]
- Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine. [europepmc]
- Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data. [europepmc]
- In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. [europepmc]
- Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. [europepmc]
- Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. [europepmc]
- Monoclonal Antibodies and Fc-Fusion Proteins for Pediatric Use: Dosing, Immunogenicity, and Modeling and Simulation in Data Submitted to the US Food and Drug Administration. [europepmc]
- Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis. [europepmc]
- Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. [europepmc]
- Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. [europepmc]
- Current Approaches and Techniques in Physiologically Based Pharmacokinetic (PBPK) Modelling of Nanomaterials. [europepmc]
- Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients. [europepmc]
- Quantitative systems pharmacology and the personalized drug-microbiota-diet axis. [europepmc]
- Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling. [europepmc]
- Application of a Physiologically Based Pharmacokinetic Approach to Predict Theophylline Pharmacokinetics Using Virtual Non-Pregnant, Pregnant, Fetal, Breast-Feeding, and Neonatal Populations. [europepmc]
Related